DPP IV Inhibitors in The Management of  Patients With Type 2 Diabetes

DPP IV Inhibitors in The Management of Patients With Type 2 Diabetes

Dr. Anthony J. Cannon examines the DPP IV pharmacologic classes of anitdiabetic agents and looks at its ability to lower A1C values in addition to measuring their effects on hypoglycemic potential, weight and overall safety profile.


Published

January 1, 2017

Created by

National Medical Association

Related Presenters

Cannon

Anthony Cannon, MD

Internal Medicine

Anthony J. Cannon, M.D., FACE, is board certified in internal medicine and endocrinology. He received his medical degree from Cornell University Medical College in New York, New York. He completed an internship in Internal Medicine at Hartford ...